



JOSHUA E. ALLEN, PHD

Senior Vice President - Research & Development

Oncoceutics, Inc.

University City Science Center, Suite 5E

Philadelphia, PA 19104

BIO: Joshua Allen discovered ONC201 and co-invented the imipridone class of compounds that are being developed by Oncoceutics. He directed the preclinical studies that identified ONC201 as an anti-cancer agent, defined its preclinical profile, elucidated its mechanism of action, and extended its chemical structure into a new class of therapies. Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship in pharmacology at the Penn State Cancer Institute. Dr. Allen has authored several research publications and awarded grants for preclinical and clinical development of novel therapies and biomarkers. Several awards have recognized his entrepreneurial research and development efforts in different areas of oncology, including recognition on the 2016 Forbes 30 under 30 list.

PRESENTATION TITLE: *Phenotypic discovery of the first DRD2-targeting agent for clinical oncology*